Tran, Timothy H.
Chan, Albert H.
Young, Lucy C.
Bindu, Lakshman
Neale, Chris
Messing, Simon
Dharmaiah, Srisathiyanarayanan http://orcid.org/0000-0001-7630-3962
Taylor, Troy
Denson, John-Paul
Esposito, Dominic http://orcid.org/0000-0002-9987-1687
Nissley, Dwight V. http://orcid.org/0000-0001-7523-116X
Stephen, Andrew G.
McCormick, Frank http://orcid.org/0000-0002-6619-7120
Simanshu, Dhirendra K. http://orcid.org/0000-0002-9717-4618
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (HHSN261200800001E)
Article History
Received: 3 July 2020
Accepted: 26 January 2021
First Online: 19 February 2021
Competing interests
: The authors, except F.M., declare no competing interests. F.M. is a consultant for the following companies: Aduro Biotech, Amgen, Daiichi, Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, PellePharm, Pfizer, PMV Pharma, Portola Pharmaceuticals, and Quanta Therapeutics; has received research grants from Daiichi; is a recipient of funded research from Gilead Sciences; is a consultant and cofounder for the following companies (with ownership interest, including stock options): BridgeBio Pharma, DNAtrix, Olema Pharmaceuticals, and Quartz.